Skip to main content
. 2023 Jun 1;42(28):2207–2217. doi: 10.1038/s41388-023-02737-z

Fig. 6. CDK4/6 inhibitor resistant breast cancer cells have increased sensitivity to RMC-6272.

Fig. 6

Crystal violet staining of parental or Palbociclib-resistant (PalboR) MCF-7 cells grown at a series of concentrations of A palbociclib or B RMC-6272. C Quantification of crystal violet stained MCF-7, ZR752 and T47D parental and PalboR cells in response to various doses of RMC-6272 D Fraction of total cells undergoing apoptosis by YO-PRO1 staining in parental or PalboR MCF-7 cells treated with RMC-6272 for 72 h at indicated concentrations. E Immunoblot of lysate from MCF-7 parental or PalboR cells treated with the indicated doses of RMC-6272 for 24 h. Image represents at least two independent experiments. Growth of F xenografted MCF-7 PalboR cells over 28 days or G CTG-2891 PDX model over 70 days treated with the indicated drugs or the combination. Dotted line indicates the 200 m3 starting point for treatment. For MCF-7 PalboR xenograft, n = 7 mice for vehicle and RMC-6272, n = 6 combination, n = 5 palbociclib and dosing was 100 mg/kg day 0–3 before dose reduction. For CTG-2891, n = 8 palbociclib and RMC-6272, n = 7 vehicle and combination. For P values based on two-tailed Student’s t-test. P palbociclib; R RMC-6272; P + R palbociclib+RMC-6272.